PMID- 32360276 OWN - NLM STAT- MEDLINE DCOM- 20210907 LR - 20210907 IS - 2152-2669 (Electronic) IS - 2152-2650 (Print) IS - 2152-2669 (Linking) VI - 20 IP - 9 DP - 2020 Sep TI - Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. PG - 596-601 LID - S2152-2650(20)30161-0 [pii] LID - 10.1016/j.clml.2020.03.012 [doi] AB - BACKGROUND: Previous reports have suggested that a higher bone marrow plasma-cell percentage (BMPC%) is associated with worse outcomes. However, it is unknown whether BMPC% is an independent predictor because genetic information was not available at that time. Currently the impact of BMPC% at diagnosis of multiple myeloma (MM) is not well described. PATIENTS AND METHODS: We evaluated the prognostic impact of BMPC% >/= 60% versus < 60% in 1426 newly diagnosed MM patients. All patients had an estimation of their BMPC% at diagnosis, and the highest percentage was used. Progression-free survival (PFS) and overall survival (OS) analyses were performed by the Kaplan-Meier method. Univariate and multivariate analyses for PFS and OS using the Cox proportional hazards model were performed for age, Revised International Staging System (R-ISS) score, creatinine level, and BMPC%. RESULTS: BMPC% >/= 60% was found in 562 patients (39%), and the median PFS was shorter for these patients compared to BMPC% < 60% (22.6 vs. 32.1 months; P < .0001). Also, for OS, the median was shorter for the higher BMPC% group (53.4 vs. 75.4 months; P < .0001). On the multivariate analysis for PFS, age >/= 65 years (hazard ratio [HR], 1.46; P < .0001), R-ISS (1-2 vs. 3) (HR, 0.49; P < .0001), and BMPC% >/= 60% (HR, 1.23; P = .015) were predictive. On the multivariate analysis for OS, age >/= 65 years (HR, 2.23; P < .001), R-ISS (1-2 vs. 3) (HR, 0.41; P < .0001), and BMPC% >/= 60% (HR, 1.24; P = .02) were also predictive. CONCLUSION: BMPC% >/= 60% at diagnosis is predictive for PFS and OS, even in a multivariate analysis that included known prognostic factors for MM. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Al Saleh, Abdullah S AU - Al Saleh AS AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN; Department of Oncology, Division of Hematology, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. FAU - Parmar, Harsh V AU - Parmar HV AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Visram, Alissa AU - Visram A AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Muchtar, Eli AU - Muchtar E AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Buadi, Francis K AU - Buadi FK AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Go, Ronald S AU - Go RS AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Dispenzieri, Angela AU - Dispenzieri A AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Kapoor, Prashant AU - Kapoor P AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Warsame, Rahma AU - Warsame R AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Lacy, Martha Q AU - Lacy MQ AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Dingli, David AU - Dingli D AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Leung, Nelson AU - Leung N AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN; Division of Nephrology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Gonsalves, Wilson I AU - Gonsalves WI AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Kourelis, Taxiarchis V AU - Kourelis TV AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Gertz, Morie A AU - Gertz MA AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Kyle, Robert A AU - Kyle RA AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Rajkumar, S Vincent AU - Rajkumar SV AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. FAU - Kumar, Shaji K AU - Kumar SK AD - Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN. Electronic address: kumar.shaji@mayo.edu. LA - eng GR - P50 CA186781/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20200407 PL - United States TA - Clin Lymphoma Myeloma Leuk JT - Clinical lymphoma, myeloma & leukemia JID - 101525386 SB - IM MH - Aged MH - Bone Marrow/*physiopathology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multiple Myeloma/*physiopathology MH - Plasma Cells/*metabolism MH - Retrospective Studies MH - Treatment Outcome PMC - PMC7484262 MID - NIHMS1607580 OTO - NOTNLM OT - Outcome OT - Prognosis OT - Tumor burden COIS- Disclosure The authors have stated that they have no conflict of interest. EDAT- 2020/05/04 06:00 MHDA- 2021/09/08 06:00 PMCR- 2021/09/01 CRDT- 2020/05/04 06:00 PHST- 2020/02/26 00:00 [received] PHST- 2020/03/22 00:00 [revised] PHST- 2020/03/26 00:00 [accepted] PHST- 2020/05/04 06:00 [pubmed] PHST- 2021/09/08 06:00 [medline] PHST- 2020/05/04 06:00 [entrez] PHST- 2021/09/01 00:00 [pmc-release] AID - S2152-2650(20)30161-0 [pii] AID - 10.1016/j.clml.2020.03.012 [doi] PST - ppublish SO - Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):596-601. doi: 10.1016/j.clml.2020.03.012. Epub 2020 Apr 7.